OBJECTIVE： To explore the characteristics and regularities of cardiac damage induced by metranidazole， and provide reference for clinical safe application. METHODS： In retrospective study， 58 cases of cardiac damage caused by metranidazole in Henan ADR Monitoring Center for Drug from Jan. 2010 to Dec. 2015 were analyzed statistically. RESULTS： In 58 cases of cardiac damage induced by metranidazole， 25 cases were male， 33 were female， the ratio of male to female was 0.76 ∶ 1， the patients with ADR/ADE aged 15-64 years （74.14％）， most were intravenous administration （79.31％） and happened within 30 min （70.69％）， cardiac damage mainly manifested as palpitation， severe cases can cause tachycardia and arrhythmia， the ADR improved or cured after withdrawal or symptomatic treatment. CONCLUSIONS： Clinic should strengthen observation of ADR/ADE caused by metranidazole， especially the monitoring of cardiac toxicity reactions； pharmaceutical manufacturers should improve the drug instructions to insure the safety of clinical medication.